Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "Ziprasidone":

Ziprasidone Bouchette D et al. . (2019)

Intramuscular Ziprasidone Dosing for Acute Agitation in the Pediatric Emergency Department: An Observational Study. Nguyen T et al. J Pharm Pract. (2018)

Ziprasidone as a Potential Abortive Therapy for Status Migrainosus. Landsness EC et al. Neurohospitalist. (2016)

Search results

Items: 1 to 20 of 1938

1.

Neuroprotective effects of the second generation antipsychotics.

Chen AT, Nasrallah HA.

Schizophr Res. 2019 Apr 11. pii: S0920-9964(19)30134-3. doi: 10.1016/j.schres.2019.04.009. [Epub ahead of print] Review.

PMID:
30982644
2.

No Reduction in Delirium with the Use of Haloperidol or Ziprasidone in Critically Ill Patients.

Shrikant Kulkarni N.

Am Fam Physician. 2019 Apr 1;99(7):460-461. No abstract available.

PMID:
30932453
3.

Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats.

Reynolds GP, Dalton CF, Watrimez W, Jackson J, Harte MK.

Clin Psychopharmacol Neurosci. 2019 May 31;17(2):314-317. doi: 10.9758/cpn.2019.17.2.314.

4.

Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation.

Zeller S, Wilson M, Nordstrom K.

Ann Emerg Med. 2019 Apr;73(4):422-423. doi: 10.1016/j.annemergmed.2018.11.019. No abstract available.

PMID:
30902174
5.

Electroconvulsive therapy for treatment-resistant schizophrenia.

Sinclair DJ, Zhao S, Qi F, Nyakyoma K, Kwong JS, Adams CE.

Cochrane Database Syst Rev. 2019 Mar 19;3:CD011847. doi: 10.1002/14651858.CD011847.pub2.

PMID:
30888709
6.

Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China.

Yeh YC, Yu X, Zhang C, Hao W, Du F, Liu D, Yang L, Gao X.

Gen Psychiatr. 2019 Jan 4;31(3):e100016. doi: 10.1136/gpsych-2018-100016. eCollection 2018.

7.

Correction to: The Influence of a Xanthine-Catechin Chemical Matrix on in vitro Macrophage-Activation Triggered by Antipsychotic Ziprasidone.

Duarte T, Barbisan F, da Cunha BSN, Azzolin VF, Turra BO, Duarte MMMF, da Cruz Jung IE, Ribeiro EE, do Prado-Lima PA, da Cruz IBM.

Inflammation. 2019 Feb 15. doi: 10.1007/s10753-019-00974-7. [Epub ahead of print]

PMID:
30767152
8.

Clinical Outcomes in Patients Taking Inhaled Loxapine, Haloperidol, or Ziprasidone in the Emergency Department.

McDowell M, Nitti K, Kulstad E, Cirone M, Shah R, Rochford D, Walsh R, Hesse K.

Clin Neuropharmacol. 2019 Mar/Apr;42(2):23-26. doi: 10.1097/WNF.0000000000000325.

9.

Ziprasidone-loaded arabic gum modified montmorillonite-tailor-made pectin based gastroretentive composites.

Bera H, Abbasi YF, Yoke FF, Seng PM, Kakoti BB, Ahmmed SKM, Bhatnagar P.

Int J Biol Macromol. 2019 May 15;129:552-563. doi: 10.1016/j.ijbiomac.2019.01.171. Epub 2019 Jan 29.

PMID:
30707999
10.

Twenty-Four-Hour Measures of Heart Rate-Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment.

Tümüklü MN, Tümüklü MM, Nesterenko V, Jayathilake K, Beasley CM Jr, Meltzer HY.

J Clin Psychopharmacol. 2019 Mar/Apr;39(2):100-107. doi: 10.1097/JCP.0000000000001003.

PMID:
30707117
11.

Physiologically-based pharmacokinetics of ziprasidone in pregnant women.

Biesdorf C, Martins FS, Sy SKB, Diniz A.

Br J Clin Pharmacol. 2019 Jan 22. doi: 10.1111/bcp.13872. [Epub ahead of print]

PMID:
30669177
12.

Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy.

Hamner MB, Hernandez-Tejada MA, Zuschlag ZD, Agbor-Tabi D, Huber M, Wang Z.

J Clin Psychopharmacol. 2019 Mar/Apr;39(2):153-157. doi: 10.1097/JCP.0000000000001000.

PMID:
30640209
13.

Antipsychotic Use During Pregnancy and the Risk of Gestational Diabetes Mellitus: A Systematic Review.

Uguz F.

J Clin Psychopharmacol. 2019 Mar/Apr;39(2):162-167. doi: 10.1097/JCP.0000000000001002.

PMID:
30624301
14.

Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia.

Flowers SA, Baxter NT, Ward KM, Kraal AZ, McInnis MG, Schmidt TM, Ellingrod VL.

Pharmacotherapy. 2019 Feb;39(2):161-170. doi: 10.1002/phar.2214. Epub 2019 Feb 3.

PMID:
30620405
15.

A Combined Utilization of Plasdone-S630 and HPMCAS-HF in Ziprasidone Hydrochloride Solid Dispersion by Hot-Melt Extrusion to Enhance the Oral Bioavailability and No Food Effect.

Xue X, Chen G, Xu X, Wang J, Wang J, Ren L.

AAPS PharmSciTech. 2019 Jan 2;20(1):37. doi: 10.1208/s12249-018-1216-8.

PMID:
30604142
16.

The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.

Bellavia A, Centorrino F, Jackson JW, Fitzmaurice G, Valeri L.

Schizophr Res. 2018 Dec 21. pii: S0920-9964(18)30694-7. doi: 10.1016/j.schres.2018.12.006. [Epub ahead of print]

PMID:
30584025
17.
18.

The Influence of a Xanthine-Catechin Chemical Matrix on in vitro Macrophage-Activation Triggered by Antipsychotic Ziprasidone.

Duarte T, Barbisan F, da Cunha BSN, Azzolin VF, Turra BO, Duarte MMMF, da Cruz Jung IE, Ribeiro EE, do Prado-Lima PA, da Cruz IBM.

Inflammation. 2018 Dec 14. doi: 10.1007/s10753-018-0946-9. [Epub ahead of print] Erratum in: Inflammation. 2019 Feb 15;:.

PMID:
30547260
19.

A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease.

Younce JR, Davis AA, Black KJ.

J Parkinsons Dis. 2019;9(1):63-71. doi: 10.3233/JPD-181448.

20.

Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review.

Shim IH, Bahk WM, Woo YS, Yoon BH.

Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):376-382. doi: 10.9758/cpn.2018.16.4.376. Review.

Supplemental Content

Loading ...
Support Center